Clinical Ophthalmology

Intravitreal Injection of Long-Acting Anti-VEGF Agents in Retinal Disorders: Efficacy, Safety, and Future Perspectives

Intravitreal anti-VEGF therapy has revolutionized the management of a wide range of retinal diseases, including neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Despite the remarkable visual and anatomical outcomes achieved with conventional anti-VEGF agents, the need for frequent injections and regular follow up remains a significant challenge for both patients and healthcare systems. Recent advances have led to the development of long-acting anti-VEGF therapies designed to provide sustained disease control while reducing treatment burden.

The emergence of long-acting anti-VEGF agents represents an important step towards improving patient adherence, optimizing visual outcomes, and enhancing the efficiency of retinal care. These therapies have the potential to extend treatment intervals, reduce clinic visits, and address the unmet needs of patients requiring chronic management. As new therapeutic platforms continue to evolve, a comprehensive understanding of their efficacy, safety profiles, and real-world performance is essential for evidence-based clinical decision making.

This Article Collection welcomes original research articles, reviews, systematic reviews, commentaries, clinical trial reports, and protocols addressing long-acting anti-VEGF therapies in retinal diseases. Meta-analyses are welcome, but require a pre-submission check.

Topics of interest include:

• Treatment efficacy
• Durability
• Safety outcomes
• Comparative effectiveness
• Patient-reported outcomes
• Treatment adherence
• Emerging drug delivery systems
• Sustained-release technologies
• Gene-based approaches
• Future innovations in retinal therapeutics

Contributions exploring challenges, opportunities, and evolving clinical applications are particularly encouraged.

Submission Instructions:

During submission (in step 2 "About paper"), you will see a question asking "Are you interested in submitting to an article collection?" Please select the radio dial for "Yes". Then select "Intravitreal Injection of Long-Acting Anti-VEGF Agents in Retinal Disorders: Efficacy, Safety, and Future Perspectives" from the drop down menu.

All manuscripts submitted to this Article Collection will undergo full peer review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author submission instructions prior to submission. Standard Article Publishing Charges apply.

If you have any questions about this Article Collection, please contact Krista Thom at Krista.Thom@taylorandfrancis.com.

Guest Advisor:

Prof. Dr. Amin Nawar is an Associate Professor of Ophthalmology at the Faculty of Medicine, Tanta University, Egypt. He is a vitreoretinal surgeon with extensive clinical and surgical experience in the diagnosis and management of retinal diseases. His academic and research interests focus on medical and surgical retina, diabetic retinopathy, retinal vascular disorders, and emerging retinal therapies. Dr. Nawar has contributed to numerous scientific publications and is actively involved in ophthalmic education, research, and professional training.

Disclosure Statement: Prof. Dr. Nawar declares no conflicts of interest.